A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis
Open for participants age 18 to 70 with a clinical diagnosis of atopic dermatitis.
Requirements:
-
Chronic pruritus (itch) with pruritus actively present for at least 6 weeks prior to screening despite use of antihistamines or corticosteroids.
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis
Open for participants age 18 and older with a clinical diagnosis of chronic moderate-to-severe Atopic Dermatitis that has been documented for at least 2 years.
Requirements:
-
Recent history (within 6 months of screening) of inadequate response to treatment with topical medications or biologics for a stable period of 4 or more weeks.
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization
Responses in Adult and Adolescent Subjects with Moderate-to-Severe Atopic Dermatitis Treated with Nemolizumab
A Phase 2 clinical trial open for participants ages 18 to 54 with a clinical diagnosis of chronic moderate-to-severe Atopic Dermatitis that has been documented for at least 2 years.
Requirements:
-
Recent history (within 6 months of screening) of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable.
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis
Open for participants ages 2 to 11 with chronic moderate-to-severe Atopic Dermatitis for at least 3 months.
Requirements:
-
NO history of chronic asthma requiring a high dose of inhaled corticosteroids
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared with Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Open for participants age 18 to 75 with a clinical diagnosis of stable moderate-to-severe plaque psoriasis for at least 6 months prior to baseline.
​
Requirements:
-
Moderate to severe plaque psoriasis
-
Candidate for phototherapy or systemic therapy
-
Previous failure, inadequate response, intolerance, or contraindication to at least 1 conventional anti-psoriatic systemic therapy (eg, methotrexate, cyclosporine, PUVA)
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
A Phase 2b, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects with Moderate to Severe Plaque Psoriasis
Open for participants age 18 to 70 with a history of plaque psoriasis for at least 6 months prior to screening visit.
​
Requirements:
-
Moderate to severe plaque psoriasis
-
Candidate for phototherapy or systemic therapy
-
No significant flare in psoriasis for at least 3 months before screening
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.